BioNTech Reports Phase 3 Breast Cancer Trial Results
The DYNASTY-Breast02 trial met its primary endpoint of progression-free survival for a new treatment candidate.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Should pharmaceutical companies focus more on developing treatments with significant benefits than potentially limited ones?
BioNTech and DualityBio have announced results from the DYNASTY-Breast02 Phase 3 clinical trial evaluating the drug trastuzumab pamirtecan. The trial demonstrated a modest improvement in progression-free survival for patients with HR+/HER2-low metastatic breast cancer.
Why it matters
The study offers new evidence for treatment options in patients who have progressed on endocrine therapy. Understanding the balance between clinical efficacy and safety signals like interstitial lung disease is essential for future development.
The study included 541 patients randomized 1:1 to receive either trastuzumab pamirtecan or chemotherapy. While the primary endpoint was met, researchers noted a higher rate of Grade 3-5 interstitial lung disease compared to previous trials.
The players
BioNTech
A biotechnology company based in Mainz, Germany, that focuses on developing active immunotherapies for cancer and other diseases.
DualityBio
A biopharmaceutical company based in Shanghai, China, that specializes in the development of antibody-drug conjugates.
The details
The trial focused on chemotherapy-naïve patients who faced disease progression after endocrine therapy. BioNTech and DualityBio are now reviewing the findings to determine the next steps for the drug program.
Timeline
BioNTech and DualityBio released the clinical trial results on October 26, 2026.
Health Landscape
This study advances the ongoing development of antibody-drug conjugates for HER2-low breast cancer, a growing focus in precision oncology. It provides critical data that updates the efficacy and safety profile for new drug classes currently under clinical investigation.
Patients and clinicians will gain insights into potential new treatment pathways for metastatic breast cancer as data from this trial is integrated into clinical knowledge. Future updates will clarify the safety profile, specifically regarding risks like interstitial lung disease.
The takeaway
Clinical trials in oncology must balance survival benefits against serious side effects such as lung complications. Ongoing assessment of this treatment will provide a clearer picture of its long-term viability for patient care.
Further reading
Learn more about the latest breakthroughs in clinical research on the Cancer section page.
Live Poll
Should pharmaceutical companies focus more on developing treatments with significant benefits than potentially limited ones?
